Jonas Mattsson
Jonas Mattsson
Allogeneic hematopoietic stem cell transplantation (ASCT) is a well-established treatment for patients with malignant and non-malignant immunohematopoietic diseases. Matched unrelated donors are increasingly used and improved HLA matching h...
Stephen Yip,Khalid Shah
Stephen Yip
Advances in understanding neural stem cell (NSC) biology have facilitated the development of novel cell-based therapies for brain malignancies. NSCs are the most immature progenitor cells in the nervous system that have the ability to self-...
Saranya Chumsri,Angelika M Burger
Saranya Chumsri
An increased understanding of stem-cell biology at the molecular level, as well as the isolation and characterization of a rare subset of cells with tumor-initiating properties from several human tumor types, have renewed interest in the ex...
Leonard W Seymour,Ryan Cawood,Kerry D Fisher
Leonard W Seymour
Ofatumumab, a human monoclonal antibody for lymphoid malignancies and autoimmune disorders [0.03%]
奥法木单抗，一种治疗淋巴恶性肿瘤和自身免疫性疾病的全人源单克隆抗体
Tadeusz Robak
Tadeusz Robak
Genmab A/S and licensee GlaxoSmithKline plc are developing ofatumumab, an anti-CD20 human mAb, for the potential intravenous treatment of non-Hodgkin's lymphoma and autoimmune diseases, such as rheumatoid arthritis (RA) and multiple scleros...
Markalain Dery,Daniel G Bausch
Markalain Dery
The NIH and Vical Inc are developing an intramuscular needle-free DNA vaccine containing plasmids encoding the envelope glycoprotein of Ebola virus (EBOV) from the Sudan and Zaire strains, and the nucleoprotein of EBOV Zaire strain. A phase...
Catumaxomab, a rat/murine hybrid trifunctional bispecific monoclonal antibody for the treatment of cancer [0.03%]
用于癌症治疗的嵌合三功能双特异性单克隆抗体catumaxomab（商品名：Removaban）
Juqun Shen,Zhenping Zhu
Juqun Shen
Fresenius Biotech GmbH (licensed from TRION Pharma GmbH) is developing catumaxomab, a rat/murine hybrid, trifunctional, bispecific (anti-epithelial cell adhesion molecule and anti-CD3) mAb for the potential intravenous and intraperitoneal t...
Integrating genomics into clinical practice: standards and regulatory challenges [0.03%]
基因组学的临床应用：标准和监管挑战
Amnon Shabo
Amnon Shabo
Bridging between the worlds of healthcare and life sciences is crucial to realizing the personalized healthcare vision. Initiatives regarding legislation and regulation in this interdisciplinary field, along with significant advancement in ...
Challenges to the translation of genomic information into clinical practice and health policy: Utilization, preferences and economic value [0.03%]
基因组信息应用于临床实践和卫生政策的挑战：应用、偏好及经济价值
Kathryn A Phillips,Su-Ying Liang,Stephanie Van Bebber;Canpers Research Group
Kathryn A Phillips
It is important to understand how knowledge of genomics can be translated from research into clinical practice and health policies. This review examines existing evidence on three key factors in the adoption of personalized medicine: utiliz...
Peter Lea,Michael Ling
Peter Lea
Microarray multiplex protein measurement of biomarker-based molecular diagnostic and prognostic cancer testing assays is destined to become a large growth segment of the immunodiagnostic industry. Assays encompass immunohistochemistry, fluo...